AAPL   321.27 (+0.75%)
MSFT   185.05 (+0.84%)
FB   238.76 (+1.63%)
GOOGL   1,440.13 (+1.90%)
AMZN   2,447.72 (+0.44%)
NVDA   362.80 (+0.48%)
CGC   20.64 (+5.47%)
BABA   205.92 (+3.11%)
TSLA   831.98 (+1.85%)
AMD   55.88 (+0.81%)
ACB   16.04 (+0.19%)
F   5.95 (+5.31%)
GILD   72.97 (-0.50%)
NFLX   417.91 (-2.66%)
BAC   23.78 (+4.90%)
BA   143.92 (+4.65%)
AAPL   321.27 (+0.75%)
MSFT   185.05 (+0.84%)
FB   238.76 (+1.63%)
GOOGL   1,440.13 (+1.90%)
AMZN   2,447.72 (+0.44%)
NVDA   362.80 (+0.48%)
CGC   20.64 (+5.47%)
BABA   205.92 (+3.11%)
TSLA   831.98 (+1.85%)
AMD   55.88 (+0.81%)
ACB   16.04 (+0.19%)
F   5.95 (+5.31%)
GILD   72.97 (-0.50%)
NFLX   417.91 (-2.66%)
BAC   23.78 (+4.90%)
BA   143.92 (+4.65%)
AAPL   321.27 (+0.75%)
MSFT   185.05 (+0.84%)
FB   238.76 (+1.63%)
GOOGL   1,440.13 (+1.90%)
AMZN   2,447.72 (+0.44%)
NVDA   362.80 (+0.48%)
CGC   20.64 (+5.47%)
BABA   205.92 (+3.11%)
TSLA   831.98 (+1.85%)
AMD   55.88 (+0.81%)
ACB   16.04 (+0.19%)
F   5.95 (+5.31%)
GILD   72.97 (-0.50%)
NFLX   417.91 (-2.66%)
BAC   23.78 (+4.90%)
BA   143.92 (+4.65%)
AAPL   321.27 (+0.75%)
MSFT   185.05 (+0.84%)
FB   238.76 (+1.63%)
GOOGL   1,440.13 (+1.90%)
AMZN   2,447.72 (+0.44%)
NVDA   362.80 (+0.48%)
CGC   20.64 (+5.47%)
BABA   205.92 (+3.11%)
TSLA   831.98 (+1.85%)
AMD   55.88 (+0.81%)
ACB   16.04 (+0.19%)
F   5.95 (+5.31%)
GILD   72.97 (-0.50%)
NFLX   417.91 (-2.66%)
BAC   23.78 (+4.90%)
BA   143.92 (+4.65%)
Log in

TSE:PLIProMetic Life Sciences Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range
C$13.54
MA: C$13.54
C$13.54
52-Week Range N/A
Volume302 shs
Average Volume8,002 shs
Market CapitalizationC$315.66 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.
Read More
ProMetic Life Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.65 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-450-7810115

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$39.91 million
Book ValueC$6.07 per share

Profitability

Miscellaneous

Employees487
Market CapC$315.66 million
Next Earnings DateN/A
OptionableNot Optionable

Receive PLI News and Ratings via Email

Sign-up to receive the latest news and ratings for PLI and its competitors with MarketBeat's FREE daily newsletter.

ProMetic Life Sciences (TSE:PLI) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of ProMetic Life Sciences?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProMetic Life Sciences in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ProMetic Life Sciences.

Has ProMetic Life Sciences been receiving favorable news coverage?

News coverage about PLI stock has trended negative on Tuesday, InfoTrie reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ProMetic Life Sciences earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutProMetic Life Sciences.

Who are some of ProMetic Life Sciences' key competitors?

What other stocks do shareholders of ProMetic Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProMetic Life Sciences investors own include Nemaska Lithium (NMX), ProMetic Life Sciences (PFSCF), Bombardier, Inc. Class B (BBD.B), Crescent Point Energy (CPG), Sierra Wireless (SWIR), Baytex Energy (BTE), Dollarama (DOL), Parkland Fuel (PKI), Aurora Cannabis (ACB) and Resverlogix (RVX).

Who are ProMetic Life Sciences' key executives?

ProMetic Life Sciences' management team includes the following people:
  • Mr. Kenneth H. Galbraith, CEO & Director (Age 56)
  • Mr. Bruce Pritchard, International COO & Interim CFO
  • Mr. Patrick Sartore, Chief Legal Officer & Corp. Sec.
  • Mr. Bruce Wendel, Chief Bus. Devel. Officer (Age 65)
  • Dr. John Moran, Chief Medical Officer (Age 73)

What is ProMetic Life Sciences' stock symbol?

ProMetic Life Sciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PLI."

How do I buy shares of ProMetic Life Sciences?

Shares of PLI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

How big of a company is ProMetic Life Sciences?

ProMetic Life Sciences has a market capitalization of C$0.00 and generates C$39.91 million in revenue each year. ProMetic Life Sciences employs 487 workers across the globe.

What is ProMetic Life Sciences' official website?

The official website for ProMetic Life Sciences is prometic.com.

How can I contact ProMetic Life Sciences?

ProMetic Life Sciences' mailing address is 440 Armand-Frappier Blvd Suite 300, LAVAL, QC H7V 4B4, Canada. The company can be reached via phone at +1-450-7810115.

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.